Table 1 Characteristics of patients enrolled at baseline of tacrolimus treatment
From: Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients
Items | Total (N = 408) |
|---|---|
Age | 39 ± 16 |
Male gender (N, %) | 298 (73%) |
eGFR a at baseline | 105 ± 25 |
eGFR < 60 | 15 (3.7%) |
Proteinuria (g/24 h) | 6.2 (4.7–8.0) |
Serum albumin (g/L) | 24.6 ± 3.4 |
Months since renal disease onset | 6.6 (3.1–13.1) |
Months since renal biopsy | 4.6 (0.1–6.2) |
Average tacrolimus doses during induction treatment | 0.047 mg/kg |
Average tacrolimus exposure (ng/ml) b | 4.7 ± 2.1 |
Combined with RASi§ treatment | 283 (69.4%) |
Combined with corticosteroids | 383 (93.9%) |
Previous treatment with immunosuppressive drugs | 71 (17.4%) |